Please assess the completion status of the following clinical trial:

Trial Title: Thymus Transplantation With Immunosuppression

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Transplant Inclusion~* No age limit~* Thyroid studies must be done and if abnormal, must be on therapy~DiGeorge diagnosis - must have 1 symptom from the following list:~* Heart defect~* Hypocalcemia requiring replacement~* 22q11 hemizygosity~* 10p13 hemizygosity~* CHARGE association~* Abnormal ears plus mother with diabetes (type I, type II, or gestational)~Atypical Diagnosis:~* Must have, or have had, a rash. If rash present, biopsy of rash must show T cells in skin. If rash \& adenopathy resolved, must still have oligoclonal T cells.~* Within 1 month of tx must have PHA response \>20 fold above background or \>5,000 cpm, whichever is higher, or response can be \< this.~* Circulating CD3+ T cells \>50/mm3 but CD45RA+CD62L+CD3+ T cells \<50/mm or \<5% of CD3 count, whichever is higher (must be done 2x)~* Immunoscope with \>40% oligoclonal TCRBV families. A 2nd test per sponsor discretion if T cell numbers increase or activation status changes.~* If TREC done pre-tx must have TRECs \<100 per 100,000 CD3+ cells.~Typical Diagnosis:~* Circulating CD3+ CD45RA+ CD62L+ T cells and \<50/mm3 or \<5% of total T cells~* PHA response \>20 fold above background or \>5,000 cpm, whichever is higher.~* 2 studies must show similar immunological findings qualify for this study.~* TRECs, if done, should be \<100/100,000 CD3 cells~Transplant Exclusion:~* Heart surgery \<4 weeks pre-tx date~* Heart surgery anticipated w/in 3 months of proposed tx~* Rejection by surgeon or anesthesiologist as surgical candidates~* Lack of sufficient muscle tissue to accept 0.2 grams/kg transplant

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Thymus Tissue for Transplantation

Based on this trial design, predict the completion outcome and termination type (if applicable).